Guide
Ketamine Therapy Side Effects: Risks Depend on the Treatment
Ketamine therapy side effects can include sedation, dissociation, nausea and blood-pressure changes; serious risks also need to be discussed. The medicine, route, health history, other drugs and monitoring setting all matter. A clinic infusion, compounded home product and Spravato esketamine should not be treated as one identical service.
This is a guide for a clinician conversation, not a complete side-effect list or a way to judge that treatment is safe for you. If someone is hard to wake, has breathing trouble or develops another severe symptom, seek emergency help rather than waiting for a routine provider message.
Which product does the side-effect information describe?
| Treatment | The source to ask for |
|---|---|
| Spravato | Current FDA Medication Guide and the clinic's monitoring instructions |
| Ketamine injection used off-label | The product information and the prescriber's explanation of psychiatric use and monitoring |
| Compounded oral, sublingual or nasal ketamine | Pharmacy instructions, prescriber guidance and the specific home or clinic safety plan |
Spravato's current FDA Medication Guide lists its own risks. The FDA's historical compounded-ketamine warning discusses psychiatric and home-use concerns. Do not transfer a numerical side-effect rate from one treatment format to another.
Side effects to discuss before the first session
The FDA sources describe altered awareness, sleepiness, psychiatric effects, cardiovascular changes and breathing risk. Ask how the team will tell an expected short-term effect from an event that requires treatment or emergency care.
| Concern | Ask the clinician |
|---|---|
| Sedation or reduced alertness | Who observes me, and what happens if I am difficult to wake? |
| Dissociation or distress | What support is available if the experience feels frightening or overwhelming? |
| Nausea or vomiting | What is the prevention and response plan, and what instructions should I follow? |
| Blood-pressure changes | What screening and monitoring are used, and what would change the plan? |
| Breathing problems | Who can recognize and respond to this in the setting where I receive care? |
| Misuse or dependence concerns | How are prescription use and ongoing risks reviewed? |
| Urinary symptoms with ongoing use | Which symptoms should I report, and how are they evaluated? |
Sources: Spravato Medication Guide and historical FDA warning. The table is a discussion aid, not a treatment protocol.
How long do side effects last?
There is no single recovery time for every ketamine product and setting. Get written instructions for the actual treatment you receive, including work, childcare, transport and when to seek help. Do not use a marketing statement about a “short session” as permission to drive or resume demanding tasks.
For Spravato, the FDA guide says common effects, when they occur, usually happen soon after treatment and resolve the same day. That does not override its monitoring or driving restrictions. A clinician decides when you can leave, and driving is restricted until the next day after restful sleep. Other ketamine treatment requires its own instructions.
Does a difficult session mean the treatment is working?
An intense experience is not a reliable measure of clinical benefit. Report distress and side effects honestly. Ask the prescriber what they are measuring and when they will review whether the benefits justify continuing.
A provider should be able to discuss both possible benefit and reasons to change the plan. Be cautious of an explanation that treats every unpleasant experience as a necessary breakthrough or discourages you from reporting worsening symptoms.
Medicines, alcohol and health history matter
Bring the clinician a complete medicine and supplement list, including nonprescription products and substance use. Interactions and medical conditions can change the risk assessment. Do not change a dose, stop prescribed treatment or combine substances based on internet guidance.
Spravato's labeling identifies important medical contraindications and cautions, including vascular conditions, a history of bleeding in the brain, hypersensitivity, blood-pressure issues and pregnancy-related concerns. The relevant assessment is more detailed than a short list. Review the FDA guide with the clinician rather than using this page to clear yourself for care.
Longer-term risk needs an ongoing review
A reassuring first session does not answer every question about repeated use. Ask how the prescriber reviews urinary symptoms, cognition, psychiatric symptoms, medicine use and whether treatment should continue. Ask which evidence applies to the proposed duration and route.
FDA's historical warning highlights uncertainty about compounded ketamine's psychiatric benefit-risk profile and safe use. Compounded products are not FDA-approved; FDA explains the distinction here. Avoid assuming that “low dose,” “personalized” or a licensed pharmacy makes a product free of risk.
What to arrange before treatment
Get a written plan that identifies the responsible clinician, the monitoring arrangements, aftercare instructions and contact routes. Know whether support is live or delayed, and what to do outside business hours. Any required companion should know their role and the emergency plan.
Do not use this checklist to substitute for medical monitoring. A companion and a clinician perform different jobs. Our ketamine safety guide explains how to evaluate what a provider actually offers.
When to seek urgent help
Severe breathing problems, unresponsiveness or other serious symptoms need emergency assessment. A marked worsening of mental health or concern about immediate safety also needs timely professional help. Do not wait for an affiliate website, chatbot or routine consultation to respond.
For nonemergency symptoms, contact the treating clinician using the instructions supplied for your treatment. Tell them what happened and when; do not take an extra dose or make your own treatment change to compensate.
Sources and next steps
Checked November 17, 2026 against FDA medication and compounding sources. Read Spravato vs ketamine if the product distinction is unclear, and ketamine therapy for depression for evidence and follow-up questions. This page provides no individual eligibility decision or dose instructions.